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TABLE 1. Survey of United Kingdom
consultant practice
Regimen
Percent of
respondents
Warfarin 3 mo 15%
Warfarin>3 mo 0%
Aspirin 3 mo 10%
Aspirin>3 mo 48%
No medication 10%
Other regimens 17%
Letters to the Editorratio, 2.54; P ¼ .006). Stenosis-type
SVD developed early (3–4 years) in pa-
tients with PPM, whereas incompetent-
type SVD developed late (up to 9 years)
in patients without PPM. These authors
hypothesized a causative relationship of
SVD to PPM.
This report by Flameng and col-
leagues4 is the first to suggest a relation-
ship of SVD to PPM (EOAi<0.85 cm2/
m2). The other independent risk factor
for early stenotic-type SVD was valve
size of 21 mm or less. Valve size had
no relationship to incompetent-type
late SVD. Of the 564 patients, 152 had
Medtronic Mosaic (Medtronic Inc,
Minneapolis, MN) implants, and cur-
rently Flameng and colleagues4 have 7
patients being followed for early
stenosis-type SVD. Flameng and col-
leagues4 conclude by stating ‘‘by avoid-
ing PPM, the incidence of SVD should
be reduced by 50%.’’
We propose an alternative relation-
ship that SVD developing in smaller
size valve with reduced EOA may be
identified earlier because of PPM
advancing over time. The same hypoth-
esis could be related to late incompetent-
type SVD with degenerated changes not
developing stenosis in larger valves, and
consequently the development of leaflet
tears and incompetence from late SVD
causing problems of stress-related dis-
ease. In our reported study on AVR
PPM, survival was not influenced by
level of PPM, but bioprostheses was
a predictive factor.5
The challenge to us that Lawton
and colleagues’3 experience is SVD
caused by moderate PPM is not accept-
able, and further investigation is re-
quired. These valves had no
documented bioprosthetic tissue degen-
erative changes and no mineralization
of leaflet tissue on explant radiographs.
In our experience, thrombosis devel-
oped in a small percentage of Medtronic
Mosaic prostheses, possibly because of
the abnormal coagulation profile.
We do not agree with Meuris and
Flameng1 that Lawton and col-
leagues3 made the correct conclusion.
We think our observations are correct,The Journaland these valves do not have SVD de-
veloping early from moderate PPM
(in fact, we consider moderate PPM
an EOAi of> 0.65–0.75 cm2/m2; 1
of the cases should be classified as
mild PPM, 2 cases should be classi-
fied just mild at 0.83 cm2/m2, and 1
case should be classified with no
PPM at the time of implantation).
We agree with Meuris and Flameng1
that this phenomenon requires further
extensive investigation.
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To the Editor:
We read with interest the article by
ElBardissi and colleagues.1 We concur
with their conclusions that early anti-
coagulation after isolated biopros-
thetic aortic valve replacement in
patients in sinus rhythm does not
seem to reduce the risks of thrombo-
embolism, except in high-risk groups,
and that current recommendations
should be revisited.of Thoracic and Cardiovascular SurgerIn a review of this subject, we2
learned that data are not uniform owing
to the retrospective analysis of the ma-
jority of the articles. Only 2 are prospec-
tive randomized trials comparing an
antiplatelet agent with vitamin K antag-
onist3,4 and unclear anticoagulation and
antithrombotic regimens. Furthermore,
in many of the studies, the results of aor-
tic and mitral valve replacements are
combined. Despite this lack of evi-
dence, guidelines for management of
patients with valvular heart disease pub-
lished by American College of Cardiol-
ogy, American Heart Association,
American College of Chest Physicians,
and European Society of Cardiology all
recommend the use of an anticoagula-
tion regimen for the first 3 months after
bioprosthetic aortic valve replacement.
ElBardissi and colleagues1 have
pointed out that practice differs widely
from these recommendations. We
carried out a survey of 194 United King-
dom consultant cardiac surgeons on an-
tithrombotic therapy after bioprosthetic
aortic valve replacement and received
171 (88%) responses (Table 1). Be-
cause of the diverse results of this sur-
vey and insufficient evidence in the
literature, like ElBardissi and col-
leagues, we believe that a randomized
trial would be necessary.
We embarked on a feasibility phase
of this trial. If a definitive randomized
trial comparing aspirin with warfarin
sodium monotherapy is considered, as-
suming a stroke rate of 1% to 5% per
person-year, 1800 patients are required
in each group. If a 3-armed trial com-
paring aspirin with warfarin or with
no therapy is considered, approxi-
mately 5400 patients are required iny c Volume 140, Number 5 1201
Letters to the Editortotal. In the United Kingdom, approxi-
mately 3500 isolated bioprosthetic aor-
tic valve replacements are performed
per annum. Assuming 50% of these pa-
tients are eligible for the study and all
units participate, the study will take
more than 4 years to complete.
One of the main difficulties we
have encountered in the feasibility
phase of this study is recruitment of
patients with pure aortic valve
disease who do not have any forms
of arrhythmia or coronary artery
disease, thus already receiving aspirin
or warfarin. Ideally, a randomized
study is necessary. Unless this is
a multicenter international trial, suffi-
cient numbers of patients cannot be
recruited. We may then have to rely
on antithrombotic therapy in the
high-risk groups.
We would like to thank the British Heart
Foundation for supporting the feasibility
phase of this study.
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We thank the authors for their
comments regarding our recent article
discussing the necessity of immediate
postoperative anticoagulation in pa-
tients with bioprosthetic aortic valves.1
Although this exact topic has been
studied repeatedly over the past de-
cade, there continues to be a lack of
consensus, primarily owing to the ab-
sence of level 1 evidence. As the au-
thors point out, despite strong
evidence to advocate for/against an-
tithrombotic therapy after biopros-
thetic aortic valve replacement,
guidelines from major international
cardiology and cardiac surgery socie-
ties continue to recommend antithrom-
botic therapy for 90 days after
bioprosthetic aortic valve replacement.
Although there have been attempts
at performing a prospective randomized
controlled trial to definitively answer
this question and establish a standard
of care,2,3 these studies have been
grossly underpowered, containing no
more than 150 patients in each group.
Depending on the parameters used to
performa power analysis, a conservative
estimate for conducting a randomized
controlled trial with an effective power
(b> 80%) would consist of at least
1500 patients in each group. As the au-
thors describe, conducting such a study
would require enrollment from multiple
high-volume centers.
The controversy and need for level 1
evidence regarding this topic are illus-
trated by the variability in antithrom-
botic therapy regimens, which has
been documented in the literature (pri-
marily in the United Kingdom).4 An-
ecdotally, in the United States, we
know of institutions and surgeons
that routinely anticoagulate with intra-
venous heparin followed by warfarin
sodium and those that provide no anti-
coagulation whatsoever. These vary-
ing practices and unclear data should
provide incentive to funding agencies
to further study this question. On one
hand, we may be placing patients at
a high risk of major bleeding events
and on the other hand, we may notCardiovascular Surgery c November 20be adequately protecting patients
from the risk of embolism. In the
meantime, however, we believe it is
important that we use the best
available evidence, which is to avoid
routine anticoagulation except in
high-risk patients.1
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ENDOVASCULAR TREATMENT
FOR TYPE B AORTIC
DISSECTIONSTo the Editor:
We read with great interest the man-
uscript by Xu and associates,1 in
which they presented their early and
midterm results of endovascular repair
for the treatment of type B aortic dis-
sections.
Although the Stanford classification
is frequently used in the current era,
the DeBakey classification seems more10
